ANN ARBOR, Mich., May 20, 2019 /PRNewswire/ — Strata Oncology, Inc., a precision oncology company, today announced that data from its Strata Trial, a nationwide observational NGS screening protocol providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, will be presented in a poster at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, from May 31-June 4, 2019.

“The Strata Trial enables routine genomic testing for advanced cancer patients at the Ochsner Health System, which has opened an array of options for targeted treatment, as well as enrollment in precision medicine clinical trials available at our cancer center,” said Marc Matrana, MD, MSc, FACP, Director of the Ochsner Precision Cancer Therapeutics Program.

“Data from the Strata Trial support the feasibility of using a system-wide genomic testing protocol to identify patients who may be eligible for biomarker-driven trials,” said Dan Rhodes, co-founder, chief executive officer, Strata Oncology. “Strata is committed to improving outcomes for patients and accelerating drug approvals through a model that integrates universal genomic sequencing for advanced cancer patients and cutting-edge clinical research.” 

Read more here.